Veracyte outlines 10%-13% revenue growth for 2026 while advancing MRD and Prosigna launches

2026-02-25 22:18:21 ET

More on Veracyte

• Veracyte: Profitable, De-Risked, And Ready To Run
• Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
• Veracyte Non-GAAP EPS of $0.53 beats by $0.12, revenue of $140.6M beats by $4.81M
• Veracyte reports Q4 preliminary revenue in the range of $138M - $140M

Read the full article on Seeking Alpha

For further details see: